Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Raymond Alderfer

Psychiatry Harrisonburg, VA Medical Doctor

NPI 1245294362 CMS profile 237377

110 Newman Ave, Harrisonburg, VA 22801

Open in the dashboard

General payments

$2,300

209 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Raymond Alderfer of Harrisonburg, VA is reported in the CMS Open Payments database as having received $2,300 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $13 1
2021 General $186 24
2020 General $468 54
2019 General $1,632 130

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raymond Alderfer
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Raymond Alderfer were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Raymond Alderfer Psychiatry median Middle half National median
2019 $1,632 $184 $59–$605 $163
2020 $468 $119 $36–$372 $114
2021 $186 $143 $43–$576 $132
2022 $13 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Sunovion Pharmaceuticals Inc. $564 80 payments
  2. Allergan Inc. $419 46 payments
  3. Neurocrine Biosciences, Inc. $311 21 payments
  4. Otsuka America Pharmaceutical, Inc. $260 14 payments
  5. Lundbeck LLC $195 12 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $143 10 payments
  7. Avanir Pharmaceuticals, Inc. $135 9 payments
  8. Janssen Pharmaceuticals, Inc $90 4 payments
  9. Shire North American Group Inc $64 4 payments
  10. Ironshore Pharmaceuticals Inc. $30 2 payments
  11. Other $89 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,298 208 payments
  2. Education $2 1 payment
Products named General payments · program years 2019–2022
  1. LATUDA $564 80 payments
  2. VRAYLAR $410 45 payments
  3. INGREZZA $295 20 payments
  4. REXULTI $260 14 payments
  5. BRINTELLIX $156 9 payments
  6. NUEDEXTA $135 9 payments
  7. Trintellix $85 6 payments
  8. VYVANSE $79 5 payments
  9. INVEGA SUSTENNA $71 3 payments
  10. INVEGA TRINZA $71 3 payments
  11. Other $246 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record